-
Teva's Copaxone reduced brain volume loss in patients, according to study
JERUSALEM — Multiple sclerosis patients treated with a drug made by Teva Pharmaceutical Industries showed a "significant" reduction in their loss of brain volume, according to a new study.
Results of a five-year study published in the Journal of the Neurological Sciences found that Copaxone (glatiramer acetate) produced significant reductions in patients' loss of brain volume compared with other disease-modifying therapies.